Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | REV1 | Q9UBZ9 | 2/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12222589 | 0.89 | ALDH1A1 (0.56) | KMT2AKDM4ESMN1; SMN2MEN1ATM | |
| SCHEMBL21842120 | 0.85 | MEN1 (0.53) | KMT2AKDM4ESMN1; SMN2MEN1ATM | |
| SCHEMBL14860509 | 0.85 | KMT2A (0.63) | KMT2AKDM4EMEN1FAAHAOC3 | |
| SCHEMBL15560514 | 0.85 | KMT2A (0.54) | KMT2AKDM4EMEN1FAAHALDH1A1 | |
| SCHEMBL4084709 | 0.84 | KMT2A (0.73) | KMT2AKDM4EMEN1ATMALDH1A1 | |
| SCHEMBL14860436 | 0.84 | ALDH1A1 (0.59) | KMT2AKDM4ESMN1; SMN2ATMFAAH | |
| SCHEMBL14860122 | 0.84 | ALDH1A1 (0.54) | KMT2AKDM4EMEN1AOC3ALDH1A1 | |
| SCHEMBL12244095 | 0.84 | ACHE (0.58) | KDM4ESMN1; SMN2FAAHALDH1A1POLB | |
| SCHEMBL14872736 | 0.83 | MEN1 (0.68) | KMT2AKDM4EMEN1FAAHALDH1A1 | |
| SCHEMBL14870350 | 0.81 | FAAH (0.55) | KMT2ASMN1; SMN2MEN1FAAHAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180360824-A1 | PROCASPASE-ACTIVATING COMPOUNDS AND METHODS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-12-20 | — | — | US | disclosed |
| US-10022371-B2 | Procaspase-activating compounds and methods | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-07-17 | — | — | US | disclosed |
| US-10022371-B2 | Procaspase-activating compounds and methods | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-07-17 | — | — | US | disclosed |
| US-10022371-B2 | Procaspase-activating compounds and methods | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-07-17 | — | — | US | disclosed |
| US-9663482-B2 | Substituted piperazinyl acetohydrazide procaspase-activating compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663482-B2 | Substituted piperazinyl acetohydrazide procaspase-activating compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160176833-A1 | ENZYME-ACTIVATING COMPOUNDS AND COMPOSITIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160176833-A1 | ENZYME-ACTIVATING COMPOUNDS AND COMPOSITIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-06-23 | — | — | US | disclosed |
| US-9249116-B2 | Enzyme-activating compounds and compositions | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249116-B2 | Enzyme-activating compounds and compositions | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150231132-A1 | PROCASPASE-ACTIVATING COMPOUNDS AND METHODS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2015-08-20 | — | — | US | disclosed |
| US-20150210659-A1 | PARTICULATE DRUG DELIVERY METHODS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150210659-A1 | PARTICULATE DRUG DELIVERY METHODS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-07-30 | — | — | US | disclosed |
| US-8916705-B2 | Procaspase-activating compounds and compositions | The Board of Trustees of The University of Illilnois (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916705-B2 | Procaspase-activating compounds and compositions | The Board of Trustees of The University of Illilnois (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916705-B2 | Procaspase-activating compounds and compositions | The Board of Trustees of The University of Illilnois (US) | 2014-12-23 | — | — | US | disclosed |
| WO-2014022858-A1 | ENZYME-ACTIVATING COMPOUNDS AND COMPOSITIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-02-06 | — | — | WO | disclosed |
| US-20130096133-A1 | PROCASPASE-ACTIVATING COMPOUNDS AND COMPOSITIONS | The Board of Trustees of the University lllinois (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096133-A1 | PROCASPASE-ACTIVATING COMPOUNDS AND COMPOSITIONS | The Board of Trustees of the University lllinois (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096133-A1 | PROCASPASE-ACTIVATING COMPOUNDS AND COMPOSITIONS | The Board of Trustees of the University lllinois (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210659-A1 | PARTICULATE DRUG DELIVERY METHODS | CASP3, BAX, CASP5 | KMT2A 3969/4885KDM4E 1974/4885SMN1; SMN2 3012/4885 |
| US-20150231132-A1 | PROCASPASE-ACTIVATING COMPOUNDS AND METHODS | CASP3, CASP5, CASP6 | KMT2A 3185/4885KDM4E 1115/4885SMN1; SMN2 3087/4885 |
| US-20180360824-A1 | PROCASPASE-ACTIVATING COMPOUNDS AND METHODS | CASP3, CASP5, CASP6 | KMT2A 3185/4885KDM4E 1115/4885SMN1; SMN2 3087/4885 |
| US-20130096133-A1 | PROCASPASE-ACTIVATING COMPOUNDS AND COMPOSITIONS | CASP3, CASP5, CASP6 | KMT2A 3351/4885KDM4E 1130/4885SMN1; SMN2 3100/4885 |
| US-10022371-B2 | Procaspase-activating compounds and methods | CASP3, CASP5, CASP6 | KMT2A 3185/4885KDM4E 1115/4885SMN1; SMN2 3087/4885 |
| US-20160176833-A1 | ENZYME-ACTIVATING COMPOUNDS AND COMPOSITIONS | RNASE1, CASP3, CASP5 | KMT2A 2765/4885KDM4E 1464/4885SMN1; SMN2 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.